XML 112 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Goodwill and Other Intangible Assets
12 Months Ended
Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block]
.
Goodwill and Other Intangible Assets
 
Goodwill recorded as of December 31, 2014 of $15.5 million is attributable to the 2014 acquisition of RedPath. Goodwill recorded as of December 31, 2013 was attributable to the 2010 acquisition of Group DCA and has been reclassified as held-for-sale. See Note19, Discontinued Operations for further information.

Goodwill
In connection the Company's decision to dispose of Group DCA, the Company reclassed the $2.5 million goodwill balance to assets held-for-sale within Other non-current assets in the consolidated balance sheet as of December 31, 2014 and impaired $1.2 million of the goodwill associated with the 2010 acquisition of Group DCA as the fair value of the Group DCA reporting unit was below its carrying value including goodwill, leaving a balance of $1.3 million. A rollforward of the carrying value of goodwill from continuing operations from January 1, 2014 to December 31, 2014 is as follows:
 
2014
 
January 1,
Additions
Adjustments
Impairments
December 31,
RedPath
$

$
15,545

$

$

$
15,545


Other Intangible Assets
The net carrying value of the identifiable intangible assets as of December 31, 2014 is as follows: 
 
 
 
As of December 31, 2014
 
Life
 
Carrying
Accumulated
 
 
(Years)
 
Amount
Amortization
Net
Diagnostic assets:
 
 
 
 
 
Asuragen acquisition:
 
 
 
 
 
   Thyroid
9
 
$
8,519

$

$
8,519

   Pancreas
7
 
2,882

154

2,728

   Biobank
4
 
1,575

147

1,428

RedPath acquisition:
 
 
 
 
 
Pancreas test
7
 
16,141

385

15,756

Barrett's test
9
 
18,351


18,351

Total
 
 
$
47,468

$
686

$
46,782

Diagnostic lab:
 
 
 
 
 
CLIA Lab
2.3
 
$
609

$
87

$
522



Amortization expense was $0.8 million for the year ended December 31, 2014. There was no amortization expense for the year ended December 31, 2013. Amortization of the thyroid diagnostic asset will begin upon launch of the product. Estimated amortization expense for the next five years is as follows:

2015
2016
2017
2018
2019
$
5,102

$
6,358

$
6,097

$
5,949

$
5,703